Icosapent Ethyl Capsules
Dosage form: capsule
Drug class:Miscellaneous antihyperlipidemic agents
Medically reviewed by Drugs.com. Last updated on Feb 1, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Indications and Usage for Icosapent Ethyl Capsules
Icosapent Ethyl Capsules are indicated:
- as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.
Limitations of Use:
The effect of Icosapent Ethyl Capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Icosapent Ethyl Capsules Dosage and Administration
Prior to Initiation of Icosapent Ethyl Capsules
- Assess lipid levels before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high triglyceride levels and manage as appropriate.
- Patients should engage in appropriate nutritional intake and physical activity before receiving Icosapent Ethyl Capsules, which should continue during treatment with Icosapent Ethyl Capsules.
2.2 Dosage and Administration
- The daily dose of Icosapent Ethyl Capsules is 4 grams per day taken as:
- two 1 gram capsules twice daily with food.
- Advise patients to swallow Icosapent Ethyl Capsules whole. Do not break open, crush, dissolve, or chew Icosapent Ethyl Capsules.
Dosage Forms and Strengths
Icosapent Ethyl Capsules are supplied as:
- 1 gram oblong, natural colored transparent soft gelatin capsules with the logo “A1000” printed in white ink.
Contraindications
Icosapent Ethyl Capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to icosapent ethyl or any of its components.
Warnings and Precautions
Atrial Fibrillation/Flutter
Icosapent Ethyl Capsules are associated with an increased risk of atrial fibrillation..